MHRA

Breakthrough lung cancer drug gets MHRA green light

NHS lung cancer patients will be the first in Europe to be offered sotorasib.

Ronapreve may prevent infections and help reduce hospital admissions.

The decision will make it easier for patients to access the painkiller, says the regulator.

Framework to cover new types of medicines that are manufactured and supplied at the point of care.

Batches recalled as a precautionary measure due to contamination.

UK medicines watchdog the MHRA has announced that the first progesterone pills are to be available from pharmacies without a prescription.

Product information updated for Pfizer/BioNTech and Moderna vaccines - insufficient evidence to justify new warning for AZ vaccine.

MHRA is urgently recalling packs of Co-codamol effervescent tablets amid concerns they may contain too much or too little of the active ingredients.

Some 113,000 websites operating illegally in the UK were removed or had their URLs blocked as part of Operation Pangea.

Small number have reported symptoms consistent with thyroid dysfunction when their tablets were changed to a different product.

The MHRA has launched a consultation on whether Nuromol should be available to patients without having to visit a pharmacy.

Some batches of Syonell 250mg and 500mg gastro-resistant tablets have product packaging information errors.

Five people are suspected of selling unlicensed medicines through illegal websites.

Batches of Itraconazole 10mg/ml oral solution have been recalled by the MHRA.

Most reports relate to injection site reactions and generalised symptoms reflecting a normal immune response to the vaccine.

Making the contraceptive pill available over the counter will increase access and “enable women to make an informed choice" says RPS.

Pharmacists could be able to sell the contraceptive pill after MHRA consultation on reclassification.

The MHRA has said an analysis on approved Covid vaccines shows they are safe despite mild side-effects.

A batch of Instanyl 100mcg nasal spray solution has been recalled following safety concerns.

The MHRA has granted a ‘promising innovative medicine’ designation to experimental RSV drug nirsevimab.